Hamilton Beach Brands Holding Company — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; comparison is with Q1 2023 unless otherwise noted. Hamilton Beach Brands, Inc. is the Company’s sole operating segment. Its businesses include consumer and commercial appliances, licensing, and healthcare-management connected devices and software.
Financial performance
- Revenue: $128.3 million, essentially unchanged year over year. Unit volume rose 8%, with more favorable product mix, but lower average selling prices offset those gains. Consumer product revenue was $112.8 million, commercial $13.5 million, licensing $1.6 million, and leasing $0.5 million.
- Gross profit and margin: $30.1 million and 23.4%, up from $20.9 million and 16.3%. Lower product costs and favorable mix drove the improvement, partly offset by a $0.7 million non-cash warehouse lease impairment.
- Operating and net results: Operating loss narrowed to $0.9 million from $5.1 million. SG&A increased $5.0 million to $30.9 million, including approximately $1.0 million of HealthBeacon acquisition costs that management says will not recur, HealthBeacon expenses, and higher employee-related and stock compensation costs. Net loss was $1.2 million, or $0.08 per diluted share, versus $4.8 million, or $0.34 per share. Net interest expense fell to $0.2 million from $1.3 million, primarily reflecting lower average borrowings and interest rates.
- Cash flow: Operating activities provided $19.7 million, compared with $34.9 million. Management attributed the decrease mainly to incentive compensation paid in Q1 2024 and prior-year inventory reduction. Investing activities used $6.7 million, including the HealthBeacon acquisition; financing activities used $2.1 million. Ending cash and cash equivalents were $26.3 million; cash, cash equivalents and restricted cash totaled $27.2 million.
- Liquidity and debt: At March 31, 2024, revolving borrowings were $50.0 million, unchanged from year-end and below $79.3 million a year earlier. The $150 million facility had a $120.5 million borrowing base and $70.5 million excess availability. The weighted-average facility rate was 3.17%, including swaps. The Company reported compliance with financial covenants and expects cash, facility availability, and operating cash flows to cover needs for the next 12 months. The facility expires June 30, 2025.
- Balance sheet: Total assets were $369.0 million and stockholders’ equity was $145.4 million at quarter-end. Inventory was $133.5 million; accounts payable was $96.6 million.
Material changes, outlook, and risks
- Sales increased in Latin American and Mexican consumer markets but declined in U.S. and Canadian consumer markets; global commercial sales rose slightly. Management emphasized that results are highly seasonal, with most revenue and operating profit typically generated in the second half. Q1 results are not necessarily indicative of the full year.
- The Company acquired HealthBeacon on February 2 for approximately $7.5 million, funded with cash. HealthBeacon contributed $0.6 million revenue and $1.1 million operating loss after acquisition; purchase accounting remains preliminary. The Company also incurred approximately $1.0 million in acquisition transaction costs. No formal financial guidance is provided in the filing.
- Management does not expect voluntary facility repayments in the next 12 months, noting that returns on excess cash currently exceed the facility’s average interest cost; a material decrease in interest rates could prompt reassessment. Dividends and facility availability are subject to credit-agreement conditions.
- Key exposures include consumer demand and pricing, product mix, sourcing and transportation constraints and costs, tariffs, foreign exchange, competition, customer or supplier losses, product liability and returns, and successful integration of acquisitions. The filing reports no material change to previously disclosed risk factors.
- Environmental remediation obligations accrued were $3.3 million; additional costs of up to $1.5 million were considered reasonably possible. The U.S. pension plan termination is expected to be completed in 2024; $6.6 million of deferred pension loss in accumulated other comprehensive income will be recognized as termination or settlements occur.
- Supplier-finance obligations included in accounts payable were $54.8 million at quarter-end. The Company also sold $30.1 million of U.S. receivables on a non-recourse basis during the quarter. These arrangements affect working-capital and cash-flow interpretation.
Important facts for investors to verify
- Whether improved gross margin persists as selling prices, product mix, and product costs evolve.
- HealthBeacon’s operating performance, integration progress, and final purchase-price allocation, including potential effects of valuation changes.
- Cash generation and working-capital trends, particularly receivables sales, supplier-finance balances, and inventory.
- Facility renewal or refinancing plans ahead of the June 2025 expiration, covenant headroom, and the impact of floating rates despite interest-rate swaps.
- Seasonal demand and the extent to which second-half sales and profits meet management’s expectations; the filing provides no numerical guidance.
- Developments in environmental remediation and pension-plan termination costs and timing.